Cyclacel's cancer drug sapacitabine gets FDA's orphan-drug status

07/1/2010 | Reuters

The FDA granted orphan-drug designation to sapacitabine, Cyclacel Pharmaceuticals' experimental drug for acute myeloid leukemia and bone marrow stem cell disorder. The drugmaker plans to proceed with pivotal late-stage trials of the product this year.

View Full Article in:

Reuters

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Counsel – Regulatory Affairs
RAI Services Company
Winston Salem, NC
Director of Program Development
AdvaMed
Washington DC, DC
Director of System QA
LifeWatch Services, Inc.
Rosemont, IL
Director of Business Development and Membership
AdvaMed
Washington DC, DC
Director, Corporate Counsel
Regeneron
Tarrytown, NY